PITTSBURGH, April 1, 2005 /PRNewswire-FirstCall via COMTEX/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Quinapril Hydrochloride and Hydrochlorothiazide Tablets, 10 mg/12.5 mg, 20 mg/12.5 mg and 20 mg/25 mg. Quinapril Hydrochloride and Hydrochlorothiazide Tablets are the generic version of Pfizer Pharmaceuticals' Accuretic^® Tablets.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories, Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

SOURCE Mylan Laboratories Inc.

Media, Heather Bresch,
or Investors,
Kris King,
both of Mylan Laboratories Inc.,
+1-724-514-1800